bluebird bio, Inc.
BLUE · NASDAQ
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | 0.09 | 0.11 | -0.23 |
| FCF Yield | -93.10% | -9.47% | -10.39% | -5.30% |
| EV / EBITDA | -6.38 | -92.33 | -24.17 | -25.21 |
| Quality | ||||
| ROIC | -18.81% | -11.17% | -18.59% | -19.94% |
| Gross Margin | 68.39% | 40.84% | -11.02% | -79.78% |
| Cash Conversion Ratio | 1.49 | 1.75 | 1.13 | 0.81 |
| Growth | ||||
| Revenue 3-Year CAGR | 195.39% | 185.61% | 117.81% | 25.54% |
| Free Cash Flow Growth | 12.53% | 26.82% | -4.37% | 13.26% |
| Safety | ||||
| Net Debt / EBITDA | -4.45 | -32.90 | -7.41 | -4.15 |
| Interest Coverage | -4.28 | -6.39 | -11.58 | -16.21 |
| Efficiency | ||||
| Inventory Turnover | 0.15 | 0.35 | 0.22 | 0.87 |
| Cash Conversion Cycle | 308.48 | 160.29 | 346.38 | 95.60 |